FIELD: biotechnology.
SUBSTANCE: invention relates to use of the composition for treating uveal melanoma, reducing tumor growth in uveal melanoma and/or initiating regression of uveal melanoma. Said composition contains an antibody-drug conjugate (ADC), containing a bispecific antigen-binding molecule and maytansinoid. Said bispecific antigen-binding molecule comprises a first antigen-binding domain (D1) containing HCDR1–HCDR3 with sequences SEQ ID NO: 60, 62, 64 and LCDR1–LCDR3 with sequences SEQ ID NO: 140, 142, 144, as well as a second antigen-binding domain (D2), (D1) containing HCDR1–HCDR3 with sequences SEQ ID NO: 84, 86, 88 and LCDR1–LCDR3 with sequences SEQ ID NO: 140, 142, 144.
EFFECT: invention provides destruction of c-Met expressing cells of uveal melanoma.
17 cl, 33 dwg, 44 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
| ANTI-MET ANTIBODIES AND THEIR USE | 2017 |
|
RU2765267C2 |
| ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES | 2020 |
|
RU2831608C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
